Comparative tolerability of pharmacological treatments for patent ductus arteriosus

Drug Safety

Volumn 24, Issue 7, 2001, Pages 537-551

  Hammerman, C ^a   Kaplan, M ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; FUROSEMIDE; IBUPROFEN; INDOMETACIN; MEFENAMIC ACID; PROSTAGLANDIN; PROSTAGLANDIN RECEPTOR AFFECTING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

BRAIN BLOOD FLOW; DRUG TOLERABILITY; HUMAN; INTESTINE BLOOD FLOW; KIDNEY BLOOD FLOW; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VASOCONSTRICTION;

EID: 0034950049     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124070-00005     Document Type: Review

References (94)

1. Evaluation of the preterm infant for patent ductus arteriosus
2. Persistent patency of the ductus arteriosus in premature infants: Incidence, perinatal factors and natural history
3. Maturation of contractile response of ductus arteriosus to oxygen and drugs
4. Oxygen related prostaglandin synthesis in ductus arteriosus and other vascular cells
5. Developmental changes in constriction of the ductus arteriosus: Responses to oxygen and vasoactive substances in the isolated ductus arteriosus of the fetal lamb
6. Ontogeny of the ductus arteriosus response to prostaglandins and inhibitors of their synthesis
7. Effects of hyperventilation on prostacyclin formation and on pulmonary vasodilation after GB S induced pulmonary hypertension
8. Indomethacin and apnea of prematurity
9. Incidence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less
10. Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: The role of gestation, oxygen tension and vasavasorum
11. Inhibition of human premature labor by indomethacin
12. Congestive heart failure from suspected ductal closure in utero
13. Characteristic morphology of the constricted fetal ductus arteriosus following maternal administration of indomethacin
14. Constriction of the fetal ductus arteriosus after administration of indomethacin to the pregnant ewe
15. Further evidence implicating E-type prostaglandins in the patency of the lamb ductus arteriosus
16. Guinea pig ductus arteriosus. I. Cellular and metabolic basis for oxygen sensitivity
17. Clinical note: Relationship of maternal treatment with indomethacin to persistence of fetal circulation syndrome
18. The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus
19. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestatlonal age
20. Indomethacin in the treatment of premature labor
21. Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn
22. Neonatal Complications after the administration of indomethacin for preterm labor
23. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants
24. Antenatal indomethacin - adverse fetal effects confirmed
25. Indomethacin tocolysis impairs postnatal postnatal patent ductus arteriosus severity
26. The ductus arteriosus: Histological and clinical observations
27. Necrosis of the ductus arteriosus in premature infants
28. Histologic observation of the ductus arteriosus in premature infants with intrauterine growth retardation
29. Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates
30. Neurodevelopmental follow-up at 36 months' corrected age of preterm infants treated with prophylactic indomethacin
31. Outcome of children in the indomethacin intraventricular hemorrhage prevention trial
32. Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room
33. Prophylactic indomethacin: Factors determining permanent ductus arteriosus closure
34. Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome
35. Low-dose indomethacin therapy and extension of intraventricular hemorrhage: A multicenter randomized trial
36. Early intravenous indomethacin prolongs respiratory support in very low birth weight infants
37. Controlled study of the effects of indomethacin on cerebral blood flow velocities in newborn infants
38. Prophylactic indomethacin: Systematic review and meta-analysis
39. Intravenous indomethacin for preventing mortality and morbidity in very low birth weight in infants (Cochrane Review)
40. Effects of prophylactic low-dose indomethacin on hemodynamics in very low birth weight infants
41. Failure of prophylactic indomethacin to improve the outcome of the very low birth weight infant
42. Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants
43. Low-dose indomethacin therapy and extension of intraventricular hemmorhage: A multicenter randomized trial
44. Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus
45. Echocardiographic flow pattern of patent ductus arteriosus: A guide to indomethacin treatment in premature infants
46. Short vs. prolonged indomethacin therapy for patent ductus arteriosus in preterm infants
47. Effects of prolonged versus acute indomethacin therapy in very low birth weight infants with patent ductus arteriosus
48. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity
49. Continuous vs. multiple rapid infusions of indomethacin: Effects on cerebral blood flow velocity
50. Patent ductus arteriosus in the premature infant
51. Effect of indomethacin on cerebral blood flow velocity of premature newborns
52. Indomethacin and cerebral blood flow in premature infants treated for patent ductus arteriosus
53. Effects of indomethacin of cerebral hemodynamics in very preterm infants
54. Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: Duration of its effects
55. The effect of indomethacin on cerebral blood flow velocity in premature infants
56. The influence of indomethacin on the autoregulatory ability of the cerebral vascular bed in the newborn lamb
57. Maintenance of cerebral circulation during hemorrhagic hypotension in newborn pigs
58. Regional cerebral blood flow velocity changes after indomethacin infusion in premature infants
59. Effect of infusion rate of indomethacin on cerebrovascular responses in preterm neonates
60. Effects on cerebral blood flow velocities of slow and rapid infusion of indomethacin
61. Recurrence of symptomatic patent ductus arteriosus in extremely premature infants treated with indomethacin
62. Recovery of prostaglandin reopening of the ductus arteriosus after indomethacin treatment in preterm infants with respiratory distress syndrome
63. Persistent responsiveness of the neonatal ductus arteriosus in immature lambs: A possible cause for reopening of patent ductus arteriosus after indomethacin induced closure
64. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus
65. Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very-low-birth-weight infants with symptomatic patent ductus arteriosus
66. Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome
67. Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants
68. The use of dopamine for the prevention of the renal side effects of indomethacin in premature infants with patent ductus arteriosus
69. Effect of dopamine on failure of indomethacin to close the patent ductus arteriosus
70. Can dopamine prevent the renal side effects of indomethacin? A prospective randomized clinical study
71. Nonsteroidal anti-inflammatory drugs
72. Therapy of symptomatic patent ductus arteriosus in preterms using mefenemic acid and indomethacin
73. Early ibuprofen administration to prevent patent ductus arteriosus in premature infants
74. Ibuprofen as effective as indomethacin for patent ductus arteriosus
75. A Comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus
76. Treatment of patent ductus arteriosus with ibuprofen
77. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus
78. Differential effects of ibuprofen and indomethacin in the regional circulation of the dog
79. 1, and ibuprofen on bowel ischemia
80. Effects of ibuprofen and indomethacin on the regional circulation in newborn piglets
81. The renal hemodynamic effects of ibuprofen in the newborn rabbit
82. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus
83. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus
84. 2 synthesis in neonatal cerebral microvessels
85. Does ibuprofen affect bilirubin-albumin binding in newborn infant serum?
86. Bilirubin-displacing effect of ampicillin, indomethacin, newborn infants
87. Ibuprofen and the patent ductus
88. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants
89. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates
90. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus
91. Expression of cyclooxygenases in ductus arteriosus of fetal and newborn pigs
92. The pharmacology of the ductus arteriosus
93. 2
94. Combined prostaglandin and nitric oxide inhibition facilitates permanent closure of the PDA in premature baboons